Ritter Pharmaceuticals, which is developing an oral therapy that reduces the symptoms of lactose intolerance, filed on Monday with the SEC to raise up to $17 million in an initial public offering.
The Los Angeles, CA-based company, which was founded in 2004, plans to list on the NASDAQ under the symbol RTTR. Ritter Pharmaceuticals initially filed confidentially on January 29, 2015. Aegis Capital is the sole bookrunner on the deal. No pricing terms were disclosed.
